What is the 13F Pro Quality Score for ZVRA?

13F Pro ranks ZEVRA THERAPEUTICS, INC. (ZVRA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ZVRA's current score at https://13fpro.ai/company/ZVRA (free sign-up required for the full ranking).

Which hedge funds own the most ZVRA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ZVRA include BlackRock,, FMR, Woodline Partners. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ZVRA as soon as new 13F filings post.

Where does 13F Pro source ZVRA data?

All ZEVRA THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. ZEVRA THERAPEUTICS, INC. files with the SEC under CIK 1434647. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ZVRA in?

ZEVRA THERAPEUTICS, INC. (ZVRA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ZVRA's revenue?

Per ZEVRA THERAPEUTICS, INC.'s latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: MIPLYFFA product sales ($30.2M, +40% YoY); AZSTARYS License Agreement ($0.3M, -75% YoY); OLPRUVA product sales ($0.2M, -33% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/ZVRA.

What are ZVRA's largest expenses?

ZEVRA THERAPEUTICS, INC.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($16.6M, -20% YoY); Research and development ($4.5M, +31% YoY); Cost of product revenue ($1.5M, -88% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is ZVRA research updated on 13F Pro?

ZVRA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ZEVRA THERAPEUTICS, INC.(ZVRA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1434647 ZVRA stock profile & AI dashboard →

13F Pro Quality Score

72.8/100

Rank #146 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

98.2/100

Profitability

97.3/100

Balance Sheet

96.5/100

Earnings Quality

56.8/100

Free Cash Flow

77.6/100

Institutional Flow

75.0/100

Revenue Scale

19.5/100

Dilution Risk

14.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ZVRA Scores 73/100

exact factor attribution · 2026-09-11

ZVRA's composite is driven by revenue growth and profitability, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.6 pts

98th pct

Profitability

+7.1 pts

97th pct

Capital efficiency

+4.7 pts

97th pct

Free cash flow

+4.1 pts

78th pct

Earnings growth

+1.7 pts

85th pct

Institutional flow

+1.3 pts

75th pct

Earnings quality

+0.7 pts

57th pct

Shareholder dilution

-1.8 pts

15th pct

Scale

-4.6 pts

20th pct

Latest change (2026-08-06): 66 → 72 · ↑ Free cash flow 30→83

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ZVRA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ZEVRA THERAPEUTICS, INC. (ZVRA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZVRA at 72.8/100 on a 32-signal composite quality model, placing it at rank #146 of 2,961 stocks — the top 5% of the AI-ranked universe. ZVRA scores in the top quartile across revenue growth (98.2), profitability (97.3), balance sheet strength (96.5). Areas of concern include revenue scale (19.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ZEVRA THERAPEUTICS, INC. reports quarterly revenue of $39.7M, net income of $8.8M, free cash flow of $16.8M. Top institutional holders of ZVRA by reported 13-F value include BlackRock, FMR, Woodline Partners, based on the most recent SEC filings. ZVRA trades on the Nasdaq exchange and files with the SEC under CIK 1434647. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZVRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ZEVRA THERAPEUTICS, INC. directly from SEC EDGAR. ZEVRA THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 7 and 73 since 2023, currently 72.8 — an improving long-term trajectory across 58 quarterly and live scoring snapshots.

✦

Fun facts about ZEVRA THERAPEUTICS, INC.

Quirks, history, and lore behind ZVRA — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company listed on Nasdaq, headquartered in North Carolina, focused on developing and commercializing treatments for rare diseases.
2
The Numbers
Revenue is in the tens of millions of dollars annually — tiny by pharma standards — with a market cap that hovers in the low hundreds of millions, the classic micro/small-cap biotech profile.
3
The History
The company rebranded and refocused in the early 2020s, pivoting squarely toward rare neurological and metabolic disorders after years of operating under a different identity.
4
The Secret
Its lead commercial product targets Niemann-Pick disease type C — a devastating, ultra-rare lysosomal storage disorder — giving it a near-monopoly niche in a tragically underserved patient population.
5
The Lore
The FDA granted its flagship drug Breakthrough Therapy designation, and the drug received accelerated approval — rare disease companies live and die by these regulatory milestones.
6
The Giveaway
Its commercial product MIPLYFFA (arimoclomol) for Niemann-Pick disease type C and its pipeline drug KP1077 for idiopathic hypersomnia are the twin pillars of this company that literally put "Zevra" in its name to signal a new chapter.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving ZVRA's Business? Latest 10-Q Breakdown

AI-extracted from ZEVRA THERAPEUTICS, INC.'s 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Zevra's Q2 FY2026 revenue rose 53% YoY to $39.7M on MIPLYFFA and EAP growth, flipping to $16.8M income from operations versus a $71.0M loss a year earlier that had been driven by a $58.7M OLPRUVA impairment.

Biggest Revenue Drivers

MIPLYFFA product sales$30.2M+40% YoY

Increase in product sales of MIPLYFFA drove most of the revenue growth

AZSTARYS License Agreement$0.3M-75% YoY

Royalty revenue; agreement was terminated in Q1 2026 under the Commave Settlement Agreement, so no future revenue will be recognized

Biggest Revenue Drivers

Total revenue: $39.7M+53% YoY

MIPLYFFA product sales$30.2M+40% YoY

Increase in product sales of MIPLYFFA drove most of the revenue growth

AZSTARYS License Agreement$0.3M-75% YoY

Royalty revenue; agreement was terminated in Q1 2026 under the Commave Settlement Agreement, so no future revenue will be recognized

OLPRUVA product sales$0.2M-33% YoY

Company has scaled back sales and marketing efforts for OLPRUVA while evaluating strategic alternatives

Largest Expense Items

Selling, general and administrative$16.6M-20% YoY

Decrease primarily related to lower professional fees and third-party spending, partially offset by an increase in personnel-related costs

Research and development$4.5M+31% YoY

Increase primarily due to ongoing arimoclomol efforts

Cost of product revenue$1.5M-88% YoY

Decrease primarily due to an $11.7M write-down of unsaleable inventory recorded in Q2 2025 that did not recur, partially offset by higher royalty costs from increased MIPLYFFA sales

Margins: Total operating expenses fell 13% YoY to $21.0M while revenue grew, and the absence of the prior-year $58.7M OLPRUVA intangible impairment and $11.7M inventory write-down swung income from operations to $16.8M from a $71.0M loss.

Watch Items from the Filing

The company's current single customer for product sales of MIPLYFFA and OLPRUVA is one specialty pharmacy provider, creating distribution concentration risk.
In July 2026 the EMA's CHMP adopted a negative opinion on the arimoclomol Marketing Authorization Application; Zevra has requested a re-examination, delaying European approval.
Zevra is scaling back OLPRUVA sales and marketing and evaluating strategic alternatives after limited commercial success ($0.2M revenue in Q2 2026).
The AZSTARYS License Agreement was terminated under the March 2026 Commave Settlement Agreement (total $50.0M consideration, $43.3M gain recognized in Q1 2026), eliminating future royalty revenue from that source.
Warrant liability fair value adjustment produced a $6.4M non-cash loss in the quarter, with the warrant liability balance growing to $13.2M from $9.6M at year-end 2025.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$39.7M

Net Income

Q2 2026

$8.8M

Free Cash Flow

Q2 2026

$16.8M

ROIC

Q2 2026

30.8%

D/E Ratio

Q2 2026

0.00

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+350.9% YoY

$106.5MFY 2025

FY22 $10.2MFY23 $27.5MFY24 $23.6MFY25 $106.5M

Net Income

+178.9% YoY

$83.2MFY 2025

FY22 $-26.8MFY23 $-46.0MFY24 $-105.5MFY25 $83.2M

Operating Income

+27.7% YoY

$-62.9MFY 2025

FY22 $-42.6MFY23 $-49.6MFY24 $-87.0MFY25 $-62.9M

EPS (Diluted)

+159.2% YoY

$1.35FY 2025

FY22 —FY23 —FY24 $-2.28FY25 $1.35

Total Assets

+59.8% YoY

$284.7MFY 2025

FY22 $115.5MFY23 $172.3MFY24 $178.1MFY25 $284.7M

Total Debt

+4.1% YoY

$61.9MFY 2025

FY22 —FY23 $5.1MFY24 $59.5MFY25 $61.9M

Op. Cash Flow

+97.7% YoY

$-1.6MFY 2025

FY22 $-18.7MFY23 $-33.5MFY24 $-69.7MFY25 $-1.6M

Free Cash Flow

+96.5% YoY

$-2.4MFY 2025

FY22 $-18.8MFY23 $-33.8MFY24 $-69.7MFY25 $-2.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$106.5M +350.9%	$23.6M -14.0%	$27.5M +170.3%	$10.2M -64.5%	$28.6M +115.6%	$13.3M
Net Income	$83.2M +178.9%	$-105.5M -129.1%	$-46.0M -72.0%	$-26.8M -212.9%	$-8.6M +33.0%	$-12.8M
Operating Income	$-62.9M +27.7%	$-87.0M -75.4%	$-49.6M -16.5%	$-42.6M -650.7%	$7.7M +237.8%	$-5.6M
EPS (Diluted)	$1.35 +159.2%	$-2.28	—	—	$-2.11 +34.3%	$-3.21
Total Assets	$284.7M +59.8%	$178.1M +3.4%	$172.3M +49.2%	$115.5M -13.1%	$132.9M +1086.0%	$11.2M
Total Debt	$61.9M +4.1%	$59.5M +1074.6%	$5.1M	—	—	$67.7M
Operating Cash Flow	$-1.6M +97.7%	$-69.7M -107.7%	$-33.5M -79.2%	$-18.7M -279.3%	$10.4M +638.4%	$-1.9M
Free Cash Flow	$-2.4M +96.5%	$-69.7M -105.9%	$-33.8M -79.9%	$-18.8M -282.0%	$10.3M +624.2%	$-2.0M

Get alerted when ZVRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ZEVRA THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ZVRA

BlackRock, Inc.
$73.3M5,108,871 sh
FMR LLC
$70.5M4,915,717 sh
Woodline Partners LP
$68.6M4,785,771 sh
VANGUARD CAPITAL MANAGEMENT LLC
$37.8M2,638,910 sh
Caption Management, LLC
$28.7M2,002,800 sh
Nantahala Capital Management, LLC
$25.8M1,797,476 sh
STATE STREET CORP
$24.1M1,681,999 sh
GEODE CAPITAL MANAGEMENT, LLC
$22.1M1,540,936 sh
D. E. Shaw & Co., Inc.
$18.7M1,306,949 sh
Qube Research & Technologies Ltd
$17.8M1,241,343 sh

Fund	Value	Shares
BlackRock, Inc.	$73.3M	5,108,871
FMR LLC	$70.5M	4,915,717
Woodline Partners LP	$68.6M	4,785,771
VANGUARD CAPITAL MANAGEMENT LLC	$37.8M	2,638,910
Caption Management, LLC	$28.7M	2,002,800
Nantahala Capital Management, LLC	$25.8M	1,797,476
STATE STREET CORP	$24.1M	1,681,999
GEODE CAPITAL MANAGEMENT, LLC	$22.1M	1,540,936
D. E. Shaw & Co., Inc.	$18.7M	1,306,949
Qube Research & Technologies Ltd	$17.8M	1,241,343

Companies Similar to ZVRA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CRMD

CorMedix Inc.

AI score

Similar quality profile · 6 shared holders

ROYCE & ASSOCIATES LP Hennion & Walsh Asset Management, Inc.AVIVA PLC

ETON

Eton Pharmaceuticals, Inc.

AI score

Similar quality profile · 5 shared holders

Nantahala Capital Management, LLC Diametric Capital, LP China Universal Asset Management Co., Ltd.

AUPH

Aurinia Pharmaceuticals Inc.

AI score

Similar quality profile · 7 shared holders

EntryPoint Capital, LLC AVIVA PLC Diametric Capital, LP

DCTH

DELCATH SYSTEMS, INC.

AI score

Similar quality profile · 7 shared holders

Propel Bio Management, LLC Diametric Capital, LP Simplify Asset Management Inc.

MGTX

MeiraGTx Holdings plc

AI score

Similar quality profile · 8 shared holders

683 Capital Management, LLC Hennion & Walsh Asset Management, Inc.EntryPoint Capital, LLC

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 8 shared holders

GLOBEFLEX CAPITAL L P Diametric Capital, LP ROYCE & ASSOCIATES LP

TBPH

Theravance Biopharma, Inc.

AI score

Similar quality profile · 5 shared holders

AVIVA PLC GLOBEFLEX CAPITAL L P MARTINGALE ASSET MANAGEMENT L P

BLFS

BIOLIFE SOLUTIONS INC

AI score

Similar quality profile · 1 shared holders

ROYCE & ASSOCIATES LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ZVRA on your watchlist

Track score changes the day ZEVRA THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ZVRA a good stock to buy?

13F Pro's AI-powered analysis of ZEVRA THERAPEUTICS, INC. (ZVRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZVRA are available on the ZVRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ZVRA is classified as a small company.

Which hedge funds own ZVRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZVRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ZEVRA THERAPEUTICS, INC.'s investment landscape.